Spots Global Cancer Trial Database for Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Official Title: A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Study ID: NCT01706666
Study Description
Brief Summary: This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bortezomib is more effective with or without combination chemotherapy in the post transplant setting.
Detailed Description: PRIMARY OBJECTIVES: I. To compare the stringent complete response (sCR) rate after 12 cycles among arms. SECONDARY OBJECTIVES: I. To compare progression-free and overall survival among arms. II. To describe the adverse event profile of each arm. TERTIARY OBJECTIVES: I. To compare sCR after 6 cycles and 24 cycles and quality of life among arms. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM A: Patients receive bortezomib subcutaneously (SC) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM B: Patients receive bortezomib SC as in Arm A, cyclophosphamide orally (PO) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM C: Patients receive bortezomib SC as in Arm A and lenalidomide PO once daily (QD) on days 1-28. In all arms, treatment continues every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 3 years.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Johns Hopkins University, Baltimore, Maryland, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Baylor Medical Center, Garland, Texas, United States
Contact Details
Name: Craig B. Reeder, M.D.
Affiliation: Mayo Clinic
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
